Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1253

Sort by

Sort Order Select

Journal Articles

A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL

Blood (2021) 137 (19): 2646–2656.

https://doi.org/10.1182/blood.2020008825

Published: 2021

Includes: Supplemental data

Journal Articles

Sirolimus with CSP and MMF as GVHD prophylaxis for allogeneic transplantation with HLA antigen–mismatched donors

Brian Kornblit, Barry E. Storer, Niels S. Andersen, Michael B. Maris, Thomas R. Chauncey, Effie W. Petersdorf, Ann E. Woolfrey, Mary E. D. Flowers, Rainer Storb, David G. Maloney, Brenda M. Sandmaier

Blood (2020) 136 (13): 1499–1506.

https://doi.org/10.1182/blood.2020005338

Published: 2020

Includes: Supplemental data

Journal Articles

Risk score to predict event-free survival after hematopoietic cell transplant for sickle cell disease

Ruta Brazauskas, Graziana M. Scigliuolo, Hai-Lin Wang, Barbara Cappelli, Annalisa Ruggeri, Courtney D. Fitzhugh, Jane S. Hankins, Julie Kanter, Joerg J. Meerpohl, Julie A. Panepinto, Damiano Rondelli, Shalini Shenoy, Mark C. Walters, John E. Wagner, John F. Tisdale, Eliane Gluckman, Mary Eapen

Blood (2020) 136 (5): 623–626.

https://doi.org/10.1182/blood.2020005687

Published: 2020

Includes: Supplemental data

Journal Articles

A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation

Blood (2020) 135 (24): 2182–2191.

https://doi.org/10.1182/blood.2019004710

Published: 2020

Includes: Supplemental data

Journal Articles

The Molecular Basis of Long First Remissions in Normal Karyotype AML Patients

Francesca Ferraro, MD PhD, Christopher A Miller, PhD, Amy Abdalla, Nichole Helton, Nathan Salomonis, PhD, Robert S Fulton, Catrina Fronick, BS, Sharon E Heath, Peter Westervelt, MD PhD, Timothy J Ley, MD

Blood (2019) 134 (Supplement_1): 3827.

https://doi.org/10.1182/blood-2019-122967

Published: 2019

Journal Articles

Dactinomycin in Acute Myeloid Leukemia with NPM1 Mutations

Guillaume Beziat, Suzanne Tavitian, MD, Sarah Bertoli, MD PhD, Francoise Huguet, MD, Laetitia Largeaud, Francois Vergez, DVM, PhD, Jean-Baptiste Rieu, PharmD, Pierre Bories, MD, Eric Delabesse, MD PhD, Christian Recher, MD PhD

Blood (2019) 134 (Supplement_1): 3900.

https://doi.org/10.1182/blood-2019-125782

Published: 2019

Journal Articles

Azacytidine Sensitizes AML Cells for Effective Elimination By CD123 CAR T-Cells

Nadia El Khawanky, Bsc(Biomed), BHlthSc(Hons), Amy Hughes, PhD, Wenbo Yu, PhD, Sanaz Taromi, PhD, Jade Clarson, BSc, Angel F. Lopez, MD PhD, Michael P. Brown, MD PhD, Justus Duyster, MD, Timothy P. Hughes, MDMBBS,FRACP,FRCPA, Deborah L. White, PhD FFSc (RCPA), Agnes S. M. Yong, MD PhD, Robert Zeiser, MD

Blood (2019) 134 (Supplement_1): 3904.

https://doi.org/10.1182/blood-2019-124684

Published: 2019

Journal Articles

Clinical and Biological Characteristics and Outcomes of Richter Transformation : A French Multicenter Study from the Filo Group

Charline Moulin, Romain Morizot, Thomas Remen, Hélène Augé, Florian Bouclet, Marion Divoux, Sandra Lomazzi, Caroline Dartigeas, MD, Anne Quinquenel, MD, Hélène Busby, MD, Cecile Tomowiak, Veronique Leblond, MD PhD, Catherine Thieblemont, MD PhD, Florence Cymbalista, MD PhD, Marie C Bene, PharmD,DPhil, Romain Guièze, MD PhD, Julien Broseus, MD PhD, Pierre Feugier, MD PhD

Blood (2019) 134 (Supplement_1): 4112.

https://doi.org/10.1182/blood-2019-128053

Published: 2019

Journal Articles

Evaluation of the Oral SYK Inhibitor Fostamatinib in Patients after Allogeneic Transplantation for Chronic Graft-Versus-Host Disease

William C. McManigle, MD, Rachel A. DiCioccio, BS, Sarah Anand, MD, Zhiguo Li, PhD, Jonathan C Poe, PhD, Krista R. Nichols, RN, MSN, AOCNS, Amy N. Suthers, PhD, Wei Jia, MD PhD, Kelly Corbet, BS, Megan Covington, BS, Julia Lloyd-Cowden, BS, Richard D. Lopez, MD, Gwynn D. Long, MD, Mitchell E. Horwitz, MD, Cristina Gasparetto, MD, Anthony D. Sung, MD, Nelson J. Chao, MD, David A. Rizzieri, MD, Stefanie Sarantopoulos, MD PhD

Blood (2019) 134 (Supplement_1): 4521.

https://doi.org/10.1182/blood-2019-130742

Published: 2019

Journal Articles

Prophylactic or Preemptive Low-Dose Azacitidine (AZA) and Donor Lymphocyte Infusion (DLI) Prevent Disease Relapse Following Allogeneic Transplantation in High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome

Thierry Guillaume, MD PhD, Pierre Peterlin, Sylvain Thepot, MD, Amandine Le Bourgeois, MD, Alice Garnier, MD, Sylvie François, MD, Corentin Orvain, Yannick Le Bris, PharmD, Clémentine Fronteau, PharmD, Patrice Chevallier, MD

Blood (2019) 134 (Supplement_1): 4555.

https://doi.org/10.1182/blood-2019-123402

Published: 2019

Journal Articles

Dramatic Resolution of HLH after Treatment with the JAK 1/2 Inhibitor, Ruxolitinib

Scott R. Goldsmith, MD, Sana Saif Ur Rehman, MD, Cara Lunn Shirai, PhD, Ravi Vij, MBBS, John F. DiPersio, MD PhD

Blood (2019) 134 (Supplement_1): 2325.

https://doi.org/10.1182/blood-2019-124176

Published: 2019

Journal Articles

De Novo Myelodysplastic Syndromes in Patients 20-50 Years Old Characterized By Frequent Mutations in TP53 and Transcription-Related Genes

Zachary D. Epstein-Peterson, MD, Barbara Spitzer, MD, Joseph McCarter, PhD, Erin McGovern, BA, Ross L. Levine, MD, Martin S. Tallman, MD

Blood (2019) 134 (Supplement_1): 2708.

https://doi.org/10.1182/blood-2019-123400

Published: 2019

Journal Articles

Phase 1 Results of CNCT19: CD19 CAR Constructed of a New Anti-CD19 Chimeric Antigen Receptor in Relapsed or Refractory Acute Lymphoblastic Leukemia

Blood (2019) 134 (Supplement_1): 2622.

https://doi.org/10.1182/blood-2019-125342

Published: 2019

Journal Articles

Impact of Bridging Chemotherapy on Clinical Outcomes of CD19 CAR T Therapy in Relapse/Refractory Diffuse Large B- Cell Lymphoma in Real World Experience

Jérôme Paillassa, MD, Laetitia Vercellino, Roberta Di Blasi, Sophie Bernard, Hannah Moatti, MD, Côme Bommier, Matteo Guerra, Veronique Meignin, Sylvie Chevret, Catherine Thieblemont, MD PhD

Blood (2019) 134 (Supplement_1): 2886.

https://doi.org/10.1182/blood-2019-129421

Published: 2019

Journal Articles

Allogeneic Transplantation for Myelodysplastic Syndrome in Adults over 50 Years Old Using Reduced Intensity/Non-Myeloablative Conditioning: Haploidentical Relative Versus Matched Unrelated Donor

Blood (2019) 134 (Supplement_1): 3323.

https://doi.org/10.1182/blood-2019-125865

Published: 2019

Journal Articles

Isavuconazole Prophylaxis during Early Phases of Allogeneic HSC Transplantation Is Not Associated to an Increase Need of Cyclosporin-a Dose Modification

Alessandra Cupri, MD, Salvatore Leotta, MD, Uros Markovic, MD, Maria Grazia Camuglia, PhD, Giulio Antonio Milone, MD, Angelo Curto Pelle, MD, Valerio Leotta, MD, Mary Ann Di Giorgio, MD, Anna Bulla, MD, Di Marco Anna Lia, PhD, Gaetano Moschetti, MD, Giuseppe Milone, MD PhD

Blood (2019) 134 (Supplement_1): 3271.

https://doi.org/10.1182/blood-2019-127120

Published: 2019

Journal Articles

Graft Versus Host Disease Leads to Elimination of Tissue-Resident Innate Lymphoid Cells Following Experimental and Clinical Allogeneic Transplantation

Paola Vinci, PhD, Elena Garcia-Martinez, MD, Margaret H. O'Connor, Anastasiya Egorova, Jason Kuttiyara, Viktor Arnhold, MD, Doris M Ponce, MD, Alan M. Hanash, MD PhD

Blood (2019) 134 (Supplement_1): 3204.

https://doi.org/10.1182/blood-2019-128966

Published: 2019

Journal Articles

Outcomes of Elderly Patients Undergoing Allogeneic Transplantation for Acute Myeloid Leukemia with Fludarabine/Melphalan or Fludarabine/TBI Conditioning Regimen

Ashley C Woods, MD, Nisha Joseph, MD, Manali Rupji, MS, Yuan Liu, PhD, Amelia Langston, MD, Edmund K. Waller, PhDMD

Blood (2019) 134 (Supplement_1): 3331.

https://doi.org/10.1182/blood-2019-130581

Published: 2019

Journal Articles

The Addition of Ibritumomab Tiuxetan (IT) to the ATG/TLI Preparative Regimen Is Safe and May Enhance Post-Transplant Response and Outcomes for Patients with Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

Michael Low Cardenas, MD, Mehrdad Abedi, MD, Christina Romo, Carol M. Richman, MD, Megan Daly, MD, Joseph Tuscano, MD

Blood (2019) 134 (Supplement_1): 3334.

https://doi.org/10.1182/blood-2019-130870

Published: 2019

Journal Articles

Early Experience Using Radiotherapy As a Salvage Treatment for Relapsed or Refractory Non-Hodgkin Lymphomas Following CD19 Chimeric Antigen Receptor Modified T-Cell Therapy

Brandon Imber, MD MA, M. Lia Palomba, MD, Carl DeSelm, MD PhD, Parastoo B. Dahi, MD, Craig S. Sauter, MD, Michael Scordo, MD, Connie Lee Batlevi, MD PhD, Jae H. Park, MD, Gunjan L. Shah, MDMS, Sergio A. Giralt, MD, Miguel-Angel Perales, MD, Michel Sadelain, MD PhD, Joachim Yahalom, MD

Blood (2019) 134 (Supplement_1): 3244.

https://doi.org/10.1182/blood-2019-129620

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL

Sirolimus with CSP and MMF as GVHD prophylaxis for allogeneic transplantation with HLA antigen–mismatched donors

Risk score to predict event-free survival after hematopoietic cell transplant for sickle cell disease

A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation

The Molecular Basis of Long First Remissions in Normal Karyotype AML Patients

Dactinomycin in Acute Myeloid Leukemia with NPM1 Mutations

Azacytidine Sensitizes AML Cells for Effective Elimination By CD123 CAR T-Cells

Clinical and Biological Characteristics and Outcomes of Richter Transformation : A French Multicenter Study from the Filo Group

Evaluation of the Oral SYK Inhibitor Fostamatinib in Patients after Allogeneic Transplantation for Chronic Graft-Versus-Host Disease

Prophylactic or Preemptive Low-Dose Azacitidine (AZA) and Donor Lymphocyte Infusion (DLI) Prevent Disease Relapse Following Allogeneic Transplantation in High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome

Dramatic Resolution of HLH after Treatment with the JAK 1/2 Inhibitor, Ruxolitinib

De Novo Myelodysplastic Syndromes in Patients 20-50 Years Old Characterized By Frequent Mutations in TP53 and Transcription-Related Genes

Phase 1 Results of CNCT19: CD19 CAR Constructed of a New Anti-CD19 Chimeric Antigen Receptor in Relapsed or Refractory Acute Lymphoblastic Leukemia

Impact of Bridging Chemotherapy on Clinical Outcomes of CD19 CAR T Therapy in Relapse/Refractory Diffuse Large B- Cell Lymphoma in Real World Experience

Allogeneic Transplantation for Myelodysplastic Syndrome in Adults over 50 Years Old Using Reduced Intensity/Non-Myeloablative Conditioning: Haploidentical Relative Versus Matched Unrelated Donor

Isavuconazole Prophylaxis during Early Phases of Allogeneic HSC Transplantation Is Not Associated to an Increase Need of Cyclosporin-a Dose Modification

Graft Versus Host Disease Leads to Elimination of Tissue-Resident Innate Lymphoid Cells Following Experimental and Clinical Allogeneic Transplantation

Outcomes of Elderly Patients Undergoing Allogeneic Transplantation for Acute Myeloid Leukemia with Fludarabine/Melphalan or Fludarabine/TBI Conditioning Regimen

The Addition of Ibritumomab Tiuxetan (IT) to the ATG/TLI Preparative Regimen Is Safe and May Enhance Post-Transplant Response and Outcomes for Patients with Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

Early Experience Using Radiotherapy As a Salvage Treatment for Relapsed or Refractory Non-Hodgkin Lymphomas Following CD19 Chimeric Antigen Receptor Modified T-Cell Therapy

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only